STOCK TITAN
  1. Home
  2. News
  3. PRCT

Procept BioRobotics Corp - PRCT STOCK NEWS

Welcome to our dedicated news page for Procept BioRobotics (Ticker: PRCT), a resource for investors and traders seeking the latest updates and insights on Procept BioRobotics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Procept BioRobotics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Procept BioRobotics's position in the market.

News
Late Breaking Abstract Presented at the Japanese Urological Association Annual Meeting on Aquablation Therapy Outcomes for Men in Japan with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia
Rhea-AI Summary

PROCEPT BioRobotics presented a late-breaking post-market survey at the Japanese Urological Association Annual Meeting on positive Aquablation therapy outcomes for men in Japan with lower urinary tract symptoms due to benign prostatic hyperplasia. The data showcased the safety and effectiveness of Aquablation therapy in treating men with BPH, highlighting reproducible results and supporting a paradigm shift in the surgical treatment of the condition.

Key highlights from the data include treating 103 men with mean age and baseline IPSS of 71 ± 7 and 18 ± 9, respectively, with a mean prostate volume of 82 ml. The data showed significant improvements in IPSS and quality-of-life scores, with no reports of pad-use incontinence or serious device-related adverse events. The results demonstrate the exceptional safety and efficacy of Aquablation therapy in Japanese men with BPH.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
PROCEPT BioRobotics Announces 12 Scientific Research Presentations on Aquablation Therapy for the Treatment of Benign Prostatic Hyperplasia at the 2024 AUA Annual Meeting
Rhea-AI Summary
PROCEPT BioRobotics announces 12 scientific research presentations on Aquablation Therapy for the treatment of Benign Prostatic Hyperplasia at the 2024 AUA Annual Meeting. The presentations include the first published experience report of same-day discharge in an ambulatory surgical center, real-world data outcomes, and a 5-year data comparison between two FDA trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5%
Tags
none
-
News
PROCEPT BioRobotics Corp. Announces Investor Event at 2024 AUA Annual Meeting in San Antonio, Texas
Rhea-AI Summary
PROCEPT BioRobotics (PRCT) to host an investor event at the American Urological Association Annual Meeting. Key executives and physicians will present at the event, with a live webcast and archived recording available for investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
none
News
PROCEPT BioRobotics to Report First Quarter 2024 Financial Results on May 1, 2024 and Attend the 2024 Bank of America Healthcare Conference on May 15, 2024
Rhea-AI Summary
PROCEPT BioRobotics (PRCT) will report Q1 2024 financial results on May 1, 2024, followed by a conference call. Management will also present at the Bank of America 2024 Health Care Conference in Las Vegas on May 15, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.02%
Tags
conferences earnings
-
News
Sonder Capital Appoints Kate Garrett as Managing Partner to Lead Next Generation of Growth
Rhea-AI Summary
Sonder Capital appoints Kate Garrett as Managing Partner, with Co-founders assuming Co-chair roles as the firm closes its second early stage fund, Sonder Futures II. Garrett brings extensive experience and success in healthcare innovation, leading the firm into its next growth phase.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.17%
Tags
partnership management
-
News
PROCEPT BioRobotics Reports Fourth Quarter and Full Year 2023 Results
Rhea-AI Summary
PROCEPT BioRobotics Corporation (PRCT) reports strong financial results for 2023 with total revenue of $136.2 million, an increase of 82% compared to 2022. The company issued a revenue guidance of $210 million for 2024, showcasing a positive growth trajectory.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.68%
Tags
earnings
News
PROCEPT BioRobotics to Present at the 44th Annual TD Cowen Health Care Conference in Boston
Rhea-AI Summary
PROCEPT BioRobotics® (PRCT) to present at the 44th Annual TD Cowen Health Care Conference in Boston. The management will present on March 5, 2024, at 12:50 p.m. Eastern Time. A live webcast and archived recording will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.44%
Tags
conferences
-
News
PROCEPT BioRobotics® Announces Preliminary Fourth Quarter Revenue of $43.3 million to $43.6 million
Rhea-AI Summary
PROCEPT BioRobotics Corporation (PRCT) Reports Strong Revenue Growth in Q4 2023, Expects 81-82% Increase in Fiscal Year 2023 Revenue
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.14%
Tags
none
-
News
Neptune Medical Appoints Dr. Fred Moll as Chairman of the Board
Rhea-AI Summary
Neptune Medical (Ticker: NPTM) appoints Dr. Fred Moll, a renowned figure in the medical technology industry, as Chairman of the Board. Dr. Moll, known as the father of medical robotics, brings extensive experience from his roles at Sonder Capital, Intuitive Surgical, and Auris Health. His appointment signifies Neptune Medical's commitment to advancing healthcare technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.09%
Tags
management
News
PROCEPT BioRobotics to Present at the 35ᵗʰ Annual Piper Sandler Healthcare Conference in New York City
Rhea-AI Summary
PRCT - PROCEPT BioRobotics to Present at 35th Annual Piper Sandler Healthcare Conference in New York City
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.02%
Tags
conferences
Stock PRCT logo
Procept BioRobotics Corp

Nasdaq:PRCT

PRCT Rankings

#1663 Ranked by Market Cap
#4434 Ranked by Stock Gains
N/A Ranked by Dividends

PRCT Stock Data

2.58B
43.88M
3.62%
91.61%
9.12%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Redwood City

About PRCT

based in silicon valley, procept biorobotics is a privately held surgical robotics company enabling better patient care by developing transformative solutions in urology. with an initial focus on benign prostatic hyperplasia (bph), the company’s first product, the aquabeam system delivering aquablation therapy, is the world’s first commercially available minimally invasive surgical robot providing autonomous tissue removal to safely and effectively treat bph. aquablation therapy offers predictable and reproducible outcomes, independent of prostate anatomy or surgeon experience.